Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, has announced a significant milestone with the 510(k) clearance from the FDA and MDR certification in the European Union for the latest version of its Trabecular Bone Score (TBS) software, TBS Osteo. This next-generation software is designed to revolutionize the evaluation of bone microarchitecture, broaden patient eligibility, and enhance connectivity within medical facilities. Medimaps plans to roll out the upgraded TBS Osteo in its current 90 global markets, making it accessible to clinicians and healthcare providers worldwide.
Univ.-Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps, emphasized the importance of these advancements in addressing the challenges faced by radiology departments. He stated, “At Medimaps, we understand the growing pressures faced by radiology departments. With the next generation of TBS Osteo, we’re equipping clinicians with the tools they need to deliver exceptional care efficiently, without compromising clinical standards.”
TBS Osteo continues to hold its position as the only approved medical device software for evaluating bone microarchitecture in clinical settings. This innovative tool has been recognized with four Category 1 reimbursement CPT codes in the United States since 2022, further solidifying its credibility and adoption in healthcare systems.
The TBS Osteo software is a critical companion to bone mineral density (BMD) measurements obtained from dual-energy X-ray absorptiometry (DXA) scans. By converting DXA scan data into precise, actionable reports, TBS Osteo complements BMD and clinical risk factors, providing clinicians with a comprehensive approach to assessing osteoporotic fracture risks. For over 14 years, Medimaps has been committed to advancing TBS Osteo, ensuring it meets the evolving needs of both patients and healthcare professionals.
Key Advancements in TBS Osteo Next Generation
The next-generation TBS Osteo introduces several significant improvements designed to enhance patient care and streamline clinical operations:
1. Inclusive Patient Care
The updated software expands its eligibility criteria beyond standard BMI ranges. With direct tissue thickness assessment, it ensures a broader, more diverse patient population can benefit from fracture risk evaluations. This inclusivity is particularly vital for addressing the needs of individuals who may not fall within conventional diagnostic parameters.
2. Seamless Connectivity
The new platform offers advanced integration capabilities, enabling medical facilities to connect multiple DXA systems. This connectivity provides secure, remote access to data from any networked computer, enhancing clinical efficiency. By streamlining operations and fostering interoperability, TBS Osteo aligns with the increasing demands for digital transformation in healthcare.
3. Enhanced Usability
A redesigned, user-friendly interface simplifies the integration of TBS Osteo into routine clinical workflows. The intuitive design ensures that clinicians can efficiently navigate the platform, reducing the learning curve and enabling faster adoption within healthcare settings.
A Trusted Tool in Bone Health Management
With over 4 million procedures performed annually, TBS Osteo has earned endorsements from more than 30 national and international clinical guidelines. Its reputation as a trusted tool in assessing and monitoring bone health extends beyond routine clinical use. The software plays a pivotal role in research and pharmaceutical clinical trials, particularly in areas such as women’s health, rheumatology, endocrinology, oncology, and sports medicine.
Bone fragility is a critical health concern in various pathologies that affect bone integrity. TBS Osteo addresses this challenge by providing clinicians with a robust, evidence-based tool for evaluating bone health. The software’s ability to integrate seamlessly with DXA systems and deliver actionable insights makes it an indispensable asset in the fight against osteoporosis and related conditions.
Expanding Global Reach
Medimaps’ decision to roll out the next-generation TBS Osteo across 90 markets underscores its commitment to making advanced bone health assessment tools accessible worldwide. The company’s strategic focus on innovation, inclusivity, and connectivity ensures that healthcare providers in diverse settings can leverage TBS Osteo to improve patient outcomes.
As the prevalence of osteoporosis continues to rise globally, the need for reliable, efficient, and inclusive diagnostic tools has never been greater. Medimaps’ TBS Osteo sets a new standard in fracture risk assessment, offering clinicians a comprehensive solution for evaluating bone health and mitigating the risks associated with bone fragility.
About Medimaps
Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.
Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company’s DNA.
Learn more at www.medimaps.ai
